Seeking to disrupt existing patterns in female health care and contribute to a future where women benefit from tailored healthcare, Leeaf is conducting a comprehensive prospective research study to verify the effectiveness of data and AI-driven treatment personalisation in increasing pregnancy and take-home baby rates for infertile couples to contribute to the improvement of fertility treatment outcomes on a larger scale.
“Our observational study collects data to develop and fine-tune the algorithms of our Leeaf solution to support IVF specialists in treatment selection. The subsequent control trial will aim to prove the efficacy of the proposed algorithms and models” says Jan Choma, Co-Founder and Co-CEO of Leeaf.
To supervise ongoing research efforts and ensure the required level of expertise, Leeaf has assembled an international scientific board composed of distinguished medical scholars and practitioners from around the world, including:
Prof. Gabor Kovacs, M.D., member of the Hungarian Academy of Science, founding president of the Szentagothai Research Center at the University of Pecs (HU), and director of the Leeaf Scientific Board.
Prof. Ivana Oborna, PhD., professor of Gynaecology and Obstetrics and Gynaecologist at Fetmed (ČR) and co-author of the Leeaf Scientific Research Study.
Associate Prof. Glenn Schattman, M.D., leader in the field of assisted reproductive technologies and fertility preservation at Weill Medical College of Cornell University in New York (USA).
United States of America
Associate Prof. Rita Vassena, PhD., CEO of Fecundis Lab, president of Eugin Ethical Committee and former member of the executive committee of the European Society of Human Reproduction and Embryology (ESHRE).
Nabil Aziz, M.D., member of the Royal College of Obstetrician and Gynaecologists (RCOG), the British Andrology Society, and the Liverpool Women's NHS Foundation Trust at Spire Liverpool Hospital (UK).
Francisco Anaya Blanes, M.D., medical director of the Reproduction Unit of the La Vega Hospital in Murcia and in charge of the surgical area in the Reproduction Unit of the Vistahermosa Clinic (ES).
“The Scientific Board we have assembled is exceptional. The support and guidance they provide us with on a daily basis has been invaluable and has allowed us to validate the scientific relevance of our intent and onboard new clinics on a monthly basis. We expect preliminary observations in March and first conclusions by the end of June,” adds Olga Chabr Grillova, Co-CEO.